Sign In
Buy ALXO
$1.67
-0.110 (-6.18%)
At Close: Jun 03, 2026
ALX Oncology to Present at the 41st Annual J.P. Morgan Healthcare Conference
07:00am, Tuesday, 03'rd Jan 2023
SOUTH SAN FRANCISCO, Calif., Jan. 03, 2023 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block t
ALX Oncology Announces Upcoming Investor Conference Participation
07:00am, Wednesday, 02'nd Nov 2022
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block
ALX Oncology Announces Upcoming Investor Conference Participation
07:00am, Thursday, 01'st Sep 2022
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2022 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block
ALX Oncology's (ALXO) Evorpacept Gets Orphan Drug Tag for GC
01:51pm, Friday, 28'th Jan 2022
The FDA bestows an Orphan Drug status to ALX Oncology's (ALXO) lead candidate, evorpacept, for treating gastric cancer and gastroesophageal junction cancer.
New Strong Sell Stocks for January 19th
07:43am, Wednesday, 19'th Jan 2022
ONEM, ALXO, and AVNS have been added to the Zacks Rank #5 (Strong Sell) List on January 19, 2022
ALX Oncology Stock (ALXO): Why The Price Fell
06:44am, Tuesday, 14'th Dec 2021
The stock price of ALX Oncology Holdings Inc (NASDAQ: ALXO) fell by 24.2% in the most recent trading session. This is why it happened.
ALX Oncology's Evorpacept Data Fails To Impress At ASH Presentation
01:58pm, Monday, 13'th Dec 2021
ALX Oncology Holdings Inc (NASDAQ: ALXO) presented initial clinical data from its ongoing Phase 1 / 2 trial evaluating evorpacept combined with azacitidine for untreated higher-risk or relapsed or
ALX Oncology Stock: Attractive After Recent Data And Slump In Price
05:34am, Tuesday, 30'th Nov 2021
ALX Oncology is developing a novel CD47 inhibitor and has differentiated itself from its competitors with its approach. Recent data updates have reaffirmed my original thoughts of their likelihood of
ALX Oncology Falls After Updated Data For Solid Tumors Candidate
11:13am, Tuesday, 09'th Nov 2021
ALX Oncology Holdings Inc (NASDAQ: ALXO) released additional data from a phase 1b trial of evorpacept in solid tumor malignancies. One cohort included gastric/gastroesophageal junction cancer patie
ALX Oncology to Present New Evorpacept Clinical Data in Myelodysplastic Syndromes at 63rd ASH Annual Meeting
09:00am, Thursday, 04'th Nov 2021
SOUTH SAN FRANCISCO, Calif., Nov. 04, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies to block t
ALX Oncology Announces Upcoming Virtual Investor Conference Participation
09:00am, Tuesday, 02'nd Nov 2021
SOUTH SAN FRANCISCO, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block
ALX Oncology Strengthens Immuno-Oncology Pipeline with Acquisition of ScalmiBio
07:00am, Thursday, 07'th Oct 2021
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company, and ScalmiBio, Inc. (“ScalmiB
-- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center -- Phase 1/2 study conducted at The University of Texas M.D. Anderson Cancer Center
ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space
11:43am, Wednesday, 08'th Sep 2021
ALX Oncology Is The Next CD47 Biotech To Watch After Recent Acquisitions In This Space
ALX Oncology Announces Upcoming Virtual Investor Conference Participation
07:00am, Tuesday, 07'th Sep 2021
BURLINGAME, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47
